Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

027IC - New Technology in the Management of Stone Disease: What’s New, What Works, & What to Buy

Saturday, May 19
10:00 AM - 12:00 PM
Location: MCC WEST, 2010

The technology used in the treatment of surgical stone disease is rapidly evolving with new capital equipment, reusable and disposable items continuously being introduced. With an increased focus on health care expenditures and outcomes, it becomes critical for the urologist to make informed decisions in this area. The majority of education originates from industry and there is a lack of non-biased resources for physicians. This two-hour instructional course will spend the first hour reviewing the latest technology in stone disease and provide evidence based overview as well as expert opinions of the performance of new products and devices. Each new technology will be reviewed by one of the faculty while the remaining panelists will provide opposing or supporting viewpoints where applicable. The relevant financial considerations of implementation will also be reviewed. In the second hour clinical case scenarios incorporating video will be presented that demonstrate the use of the technology with the goal of further assessing the value, or lack thereof, where the technology may benefit the clinical situation.

Learning Objectives:

Bodo E. Knudsen

The Ohio State University Wexner Medical Center

Bodo Knudsen, MD, FRCSC, is the Director of the OSU Comprehensive Kidney Stone Program and the Vice-Chair of Clinical Affairs at the Ohio State University Wexner Medical Center in Columbus, OH. Dr. Knudsen has practiced at Ohio State for the past 13 years. Prior to this he completed his Fellowship training in Endourology with Drs. John Denstedt and Stephen Pautler at the University of Western Ontario and his residency training under Section Chief Denis Hosking at the University of Manitoba. Dr. Knudsen has a strong passion for stone disease and his research interests center around lasers, laser fibers, and new technology in stone disease. He is a member of the R.O.C.K. Society and as well as a member of the EDGE Research Consortium.

Presentation(s):

Send Email for Bodo Knudsen

Ben H. Chew

University of British Columbia

Ben H. Chew, MD, MSc, FRCSC

Dr. Ben Chew is currently the Director of Clinical Research at the Stone Centre at Vancouver General Hospital and an Associate Professor of Urology at the University of British Columbia in Vancouver, Canada where he finished his medical school training in 1998. He completed his Urology Residency at the University of Toronto in 2003.  In 2006, he completed his Endourology and Laparoscopy Fellowship with Dr. John Denstedt in London, Ontario, Canada. His main interests lie in the treatment of kidney stone disease—both treatment and prevention. His research focus includes metabolic stone disease as well as biomaterials used in the urinary tract for ureteral stents. He has authored over 50 peer-reviewed manuscripts and book chapters including a Chapter in Campbell's Urology on Ureteroscopy.  He has won AUA Best Abstract Prizes for Stone Disease in 2005 and 2008 and best Research Prizes at the World Congress of Endourology in 2006, 2009, 2010 and 2011.  His research focus is on urinary biomaterials and ureteral stents.  He continues work on a degradable ureteral stent and has started the first-in-human trials soon. His other focus of research is on oxalate absorption and transport in the gastrointestinal tract and how it relates to stone disease. He was the Congress Co-President of the World Congress of Endourology in 2017 in Vancouver. He is part of the EDGE (Endourologic Disease Group for Excellence) Research Consortium (www.endoedge.net) as well as the Wisconsin Quality of Life Research Consortium. Recently, he was elected as the Chair of Research for the Endourology Society (www.endourology.org).

Presentation(s):

Send Email for Ben Chew

Mitchell R. Humphreys

Mayo Clinic

Dr. Mitchell Humphreys received his medical degree from the University of Missouri, went on to residency at Mayo Clinic, and completed an Endourology fellowship at Indianan university. He is a consultant and Professor in the Department of Urology at Mayo Clinic in Arizona and serves as the Dean of the Mayo School of Continuous Professional Development as well as the Endourology Fellowship director.
His clinical focus is on surgical and metabolic stone disease, BPH (with a special focus on HoLEP), and minimally invasive GU oncology. His funded research initiatives include BPH, NOTES, and a multi-institutional disease group (EDGE research consortium) in stone disease and population outcomes. He has published over 90 peer-reviewed manuscripts and multiple book chapters, as well as performs as a journal editor and reviewer. He serves as a Board of Trustee to Columbia College and is on the Board of Directors of GSD Healthcare, LLC promoting basic healthcare initiatives in underserved and impoverished areas around the globe.

Presentation(s):

Send Email for Mitchell Humphreys


Assets

027IC - New Technology in the Management of Stone Disease: What’s New, What Works, & What to Buy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for New Technology in the Management of Stone Disease: What’s New, What Works, & What to Buy